In fact, breast tumors harboring ESR1 mutations have demonstrated greater sensitivity to selective estrogen receptor modulators such as tamoxifen and fulvestrant and to the combination of these endocrine therapies with CDK4/6, PI3K, or mTORC1 inhibitors (31). The gene discussed is CDK4; the disease is breast neoplasm.